| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash | 2,887,874 | |||
| Prepaid insurance | 29,490 | |||
| Other prepaid expenses | 61,839 | |||
| Digital assets | 2,454,473 | |||
| Total current assets | 5,433,676 | |||
| Total assets | 5,433,676 | |||
| Accounts payable and accrued expenses, including 112,033 and 27,500 to related parties at september 30, 2025 and december 31, 2024, respectively | 235,900 | |||
| Research and development contract liabilities | 235,155 | |||
| Series b convertible preferred stock 8 cumulative dividend payable | 50,367 | |||
| Total current liabilities | 521,422 | |||
| Preferred stock, value-Series BConvertible Preferred Stock | 2,553,359 | |||
| Common stock, 0.0001 par value authorized 100,000,000 shares issued and outstanding 5,704,200 and 2,249,290 shares at september 30, 2025 and december 31, 2024 | 570 | |||
| Additional paid-in capital | 57,891,644 | |||
| Accumulated deficit | -55,533,319 | |||
| Total stockholders equity | 4,912,254 | |||
| Total liabilities and stockholders equity | 5,433,676 | |||
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)